SALT LAKE CITY — In this video, Jay Chhablani, MD , discusses preliminary data from the ArMaDa study of OCU410 gene therapy for geographic atrophy presented at the ARVO meeting.

In this phase 1/2 open-label dose-escalation trial, nine patients received a subretinal injection of low-dose, medium-dose or high-dose OCU410 (Ocugen), which delivers the RORA gene. After 6 months, there was a 21.4% reduction in GA lesion growth in treated eyes in three patients in the low-dose cohort compared with the fellow eye, according to Chhablani, principal investigator of Ocugen’s phase 2 data and professor of ophthalmology at University of Pittsburgh School of Medicine. Patients experienced no serious side effects related to the therapy, which targets multiple mechanisms, he said.

“We really look

See Full Page